Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms

Table 2 Demographic, clinical and pharmacological data for the 12 patients enrolled

Patient	Age at enrollment (yr)	Disease	Thiopurine dose (mg/kg per day)	5-ASA dose (mg/d)	TGN concentration1		% TGN change	NAT1 status
					Before	After
1	7.7	CD	AZA 2.6	50	244	218	-11%	Rapid
2	17.3	CD	AZA 2.2	50	2102	176	-16%	Rapid
3	17.8	CD	AZA 1.6	50	2762	101	-64%	Rapid
4	14.7	CD	6MP 1.0	50	2882	1422	-51%	Rapid
5	10.4	UC	6MP 0.6	50	3102	2062	-34%	Rapid
6	14.5	UC	6MP 0.5	50	3302	1882	-43%	Rapid
7	11.9	UC	6MP 1.0	50	228	243	+7%	Rapid
8	17.4	CD	AZA 2.2	50	2172	221	+2%	Slow
9	6.3	UC	AZA 2.3	50	375	140	-63%	Slow
10	17.5	UC	6MP 1.0	50	6472	4012	-38%	Slow
11	17.3	UC	6MP 1.0	50	264	278	+5%	Slow
12	16.6	CD	6MP 0.5	50	501	2682	-47%	Slow

¹Pmol/8 × 10⁸ erythrocytes;

²This value is the average of two measurements. 5-ASA: 5-aminosalicylate; TGN: 6-thioguanine nucleotides; NAT1: N-acetyltransferase 1; CD: Crohn’s disease; UC: Ulcerative colitis; 6MP: 6-mercaptopurine; AZA: Azathioprine.